The latest studies have demonstrated that programmed cell death protein 1 (PD-1) antibodies have exhibited significant therapeutic benefits in metastatic colorectal cancer (mCRC) patients with mismatch repair deficiency (dMMR) or microsatellite instability-high (MSI-H) as first-line treatment (1). The gene discussed is PDCD1; the disease is mismatch repair cancer syndrome 1.